West of Scotland Cancer Network Chemotherapy Protocol
|
|
- Chrystal Underwood
- 5 years ago
- Views:
Transcription
1 West of Scotland Cancer Network Chemotherapy Protocol DOCETAXEL/TRASTUZUMAB (BRWOS-005/1) Indication Docetaxel in combination with is indicated for the treatment of patients with HER2 overexpressing locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Eligibility Criteria Previous treatment should have included an adjuvant or metastatic anthracycline Patients who are HER2-ve,HER2 1+ OR HER2+ without amplification Patients with HER2 3+ or have gene amplification on FISH testing MUGA/LVEF >55% Exclusion Criteria Performance status > 2 Hypersensitivity to other taxane based therapies HER2 ve patients Patients with the following: Documented cardiac failure High risk uncontrolled arrhythmias Angina pectoris requiring medication Clinically significant valvular disease Evidence of transmural myocardial infarction on ECG Uncontrolled hypertension Dyspnoea at rest increases risk of fatal infusion related reactions to Pre-treatment evaluation Multi disciplinary review and histological information Give adequate verbal and written information for patients and their relatives regarding the patients disease, treatment and side effects Obtain written consent Formal evaluation of disease, clinical examination Document WHO performance status,height, weight and BSA If appropriate discuss potential risk of infertility/early menopause with patients Baseline investigations should include- FBC( neutrophils > 1.5, can be given if neutrophils between but only at prescribers discretion, platelets > 100), U&E s, LFT s,serum creatinine, Creatinine Clearance (>30mls/min) 1
2 Regimen Pre medication of Dexamethasone 8mg BD should be given for 3 days starting the night before Docetaxel therapy Drug Dose Route Administration Day to be given Maximum cumulative dose Docetaxel 100mg/m 2 IV IV infusion in NaCl 0.9% 250ml over 1 hour 8mg/kg (loading dose) IV IV infusion 250ml NaCL 0.9% OVER 90 MINS Day 1 Loading dose week 1 6mg/kg (every 21 days) IV IV infusion 250ml over 90mins Subsequent Weeks Day 1 As both drugs may cause hypersensitivity reactions consider giving the first dose of each drug on separate days. If there is no reaction subsequent doses may be given on the same day Repeat every 21 days for 6 cycles Stop if disease progression or unable to tolerate treatment The patient should be monitored for reactions such as fever or chills or other infusion related reactions for 6 hours after the start of the initial infusion and for 2 hours after the start of subsequent infusions. If the patient misses a dose of by one week or less, then the usual dose of (6 mg/kg) should be given as soon as possible (do not wait until the next planned cycle). Subsequent maintenance doses of 6 mg/kg should then be given every 3 weeks, according to the previous schedule. If the patient misses a dose of by more than one week, a re-loading dose of should be given (8 mg/kg over approximately 90 minutes). Subsequent maintenance doses of 6 mg/kg should then be given 3 weeks from that point. Emetogenic risk moderate refer to local policy Can offer scalp cooling Give anti emetics according to local protocol Give supportive therapy according to local protocols Is GCSF indicated? Primary prophylaxis Not recommended. Consider dose reduction instead. Secondary prophylaxis Not recommended. Consider dose reduction instead. Stem cell mobilisation Other supportive treatment: None Adverse effects Common Uncommon Lethargy, myelosuppression, total alopecia, mucositis, mild-moderate emesis, myalgia, fluid retention, altered bowel pattern, skin and nail changes, myalgia, increased sensitivity to strong sunlight, taste disturbance,altered menstrual cycle,fertility changes, hypersensitivity (see local protocol for management),hand/foot syndrome peripheral neuropathy,tear production,headache 2
3 For more detailed information refer to the full current Summary of Product Characteristics Extravasation risk category Drug Docetaxel Category Exfoliant Non-vesicant In event of an extravasation, refer to local extravastion policy Precautions & contraindications Hypersensitivity reactions are common. Patients should be observed closely especially during the first and second infusion. These reactions may occur within a few minutes of the initiation of the infusion, thus facilities for the treatment of hypotension and bronchospasm should be available. If hypersensitivity reactions occur with Docetaxel, minor symptoms such as flushing or localised cutaneous reactions do not require interruption of therapy. However, severe reactions such as severe hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation of docetaxel and appropriate therapy. Patients who develop severe hypersensitivity reactions should not be re-challenged with Docetaxel. If the patient develops an infusion related reaction (eg fever, chills) with the infusion should be stopped until symptoms have resolved and may be restarted at the same or lower rate. Serious infusion related reactions should be treated with supportive therapy such as oxygen, beta agonists and corticosteroids If bilirubin > ULN then use Docetaxel with extreme caution Pregnancy and lactation contraceptive measures should be taken Investigations prior to subsequent cycles FBC, LFT S, U & E s performance status assessment of toxicity, documented by CTC criteria version 3.,0 Drug Interactions Docetaxel - There is potential for interaction with drugs that are metabolised by cytochrome p450 eg) ketoconazole,erythromycin and therefore these drugs should be avoided or stopped -Drug interaction are unknown See BNF for full details or check with pharmacy 3
4 Dose modifications Haematology Result Value Action Platelets x 10 9 /L < 100 Delay treatment until platelets recover Neutrophils < 1 Delay treatment until neutrophils recover. Subsequent occurrence consider 20% dose reduction of Docetaxel only. Grade 4 neutropenia with sepsis Neutrophils < 1.0 and fever 38.5 C Delay until recovered then retreat at 80% Docetaxel dose/full dose Herceptin Renal Function Drug GFR % of full dose Comments No dose reduction required in renal impairment Docetaxel No dose reduction necessary Hepatic Function AST and/or ALT values Alkaline phosphatase values Docetaxel Dose modification 1.5 x ULN AND 5 x ULN no dose modification >1.5 x ULN x ULN AND 2.5 x ULN no dose modification >2.5 x ULN - 5 x ULN AND 2.5 x ULN reduce by 25% (not below 55 mg/m 2 ) >1.5 x ULN - 5 x ULN AND >2.5 x ULN - 5 x ULN reduce by 25% (not below 55 mg/m 2 ) >5 x ULN OR >5 x ULN (unless bone metastasis are present in the absence of any liver disorder) delay dose by a maximum of 2 weeks. If no recovery, discontinue docetaxel. -use with caution Toxicities Toxicity Grade Action Nausea and vomiting 1 or above Increase/change antiemetics. No dose reduction. Any Grade 3 resolving to grade 1 Consider 20% dose reduction depending on toxicity 4
5 Any Grade 4 Refer to consultant Infusion related reaction Stop infusion until symptoms improve, restart at Same or lower rate Neuropathy Grade 2 Consider 20% dose reduction Evaluation of response to treatment to be reviewed by oncologist each cycle formally re-evaluate after 3-6 cycles References Extra JM, Cognetti F, Chan S, et al. First-line trastuzumab (Herceptin) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomised phase II trial (M77001). Breast Cancer Res Treat. 2003;82(suppl 1):S47. Abstract 217 Extra JM, Cognetti F, Maraninchi D et al. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer. Abstract #555, American Society for Clinical Oncology (ASCO) Annual Meeting 2005 ABPI Medicines Compendium 2005 Summerhays M, Daniels S. Practical Chemotherapy a multidisciplinary guide. Radcliffe Medical Press, Oxford Allwood M, Stanley A, Wright P (Eds) The Cytotoxic Handbook. 4th edition. Radcliffe Medical Press, Oxford Written by Gillian Barmack, Judy Fraser,Joanne Low Approved by Mohammed Rizwanullah on behalf of the BOC breast team Date : March 2007 Review date: March
CAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1)
West of Scotland Cancer Network Chemotherapy Protocol Indication CAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1) Capecitabine (Xeloda) monotherapy is indicated for the treatment of locally advanced
More informationBreast Pathway Group Docetaxel in Advanced Breast Cancer
Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not
More informationFEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel)
FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) Indication Adjuvant or neo-adjuvant treatment for high risk early and locally advanced breast cancer. (NICE CG80) ICD-10 codes Codes
More informationLung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationBreast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen
More informationEC TH s/c Neoadjuvant Breast Cancer
EC TH s/c Neoadjuvant Breast Cancer Background: Neoadjuvant chemotherapy for inoperable locally advanced, inflammatory breast cancer or to downsize tumour prior to surgery. For patients with HER 2 positive
More informationFluorouracil, Oxaliplatin and Docetaxel (FLOT)
Fluorouracil, Oxaliplatin and Docetaxel (FLOT) Indication Perioperative chemotherapy for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. ICD-10 codes Codes with a prefix C15,C16 Regimen
More informationFOLFIRINOX (pancreas)
FOLFIRINOX (pancreas) Indication First or second line chemotherapy for metastatic pancreatic cancer. Eligible patients must be
More informationLung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in
More informationFEC-TPH (Fluorouracil, Epirubicin and Cyclophosphamide) followed by Docetaxel, Pertuzumab and Trastuzumab (Herceptin )
FEC-TPH (Fluorouracil, Epirubicin and Cyclophosphamide) followed by Docetaxel, Pertuzumab and Trastuzumab (Herceptin ) Indication Neo-adjuvant treatment for HER2 positive, locally advanced, inflammatory
More informationPertuzumab, Herceptin (Trastuzumab) and Docetaxel Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Cycle One Loading Doses Day 1 Paracetamol 1g Oral Day 1 Ondansetron 8mg Oral /Slow bolus/15 min infusion Day 1 Pertuzumab 840mg IV Infusion Pertuzumab and Herceptin can be
More informationCapecitabine plus Docetaxel in Advanced Breast Cancer
Capecitabine plus Docetaxel in Advanced Breast Cancer Indication: Palliative therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer Regimen details: Docetaxel 75mg/m 2 IV D1 Capecitabine*
More informationTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant
More informationCarboplatin and Fluorouracil
Carboplatin and Fluorouracil Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer for patients where cisplatin and / or cetuximab are not appropriate. Performance
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationDocetaxel + Carboplatin + Trastuzumab
Docetaxel + Carboplatin + Trastuzumab Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationDocetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer
Docetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer Indication: Neoadjuvant therapy f HER 2 negative high risk and fit Breast Cancer patients, suitable f a taxane containing
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationCisplatin and Fluorouracil (palliative)
Cisplatin and Fluorouracil (palliative) Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer where combination treatment with cetuximab is not indicated. PS0-1
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationPaclitaxel and Trastuzumab Breast Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel and Trastuzumab Breast Cancer PROTOCOL REF: MPHAPTRBR (Version No: 1.0) Approved for use in: HER2 positive breast cancer. For adjuvant use in T1 or T2
More informationCisplatin and Fluorouracil
Cisplatin and Fluorouracil Indication Neo-adjuvant treatment of nasopharyngeal head and neck cancer (stage II-IV) or bulky disease at other head and neck sites. Performance Status 0-1 ICD-10 codes Codes
More informationCisplatin and Fluorouracil (head and neck)
Cisplatin and Fluorouracil (head and neck) Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer where combination treatment with cetuximab is not indicated.
More informationBRAVTRAD. Protocol Code: Breast. Tumour Group: Dr. Susan Ellard. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN) and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour Group: Contact
More informationTrastuzumab (IV) Monotherapy - 7 days
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital
More informationOxaliplatin and Gemcitabine
Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen
More informationNCCP Chemotherapy Protocol
Docetaxel Monotherapy 50mg/m 2 INDICATIONS FOR USE: INDICATION In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer
More informationEC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer
EC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen EC
More informationFEC-D with HP Fluorouracil, Epirubicin, Cyclophosphamide, Followed by Docetaxel, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Approved for use in: Neoadjuvant breast cancer: The neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early breast cancer at high risk of recurrence Interim CDF funding from November
More informationBreast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer
Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Indication: Neoadjuvant therapy for patients with BRCA1/2 mutations EC Regimen details:
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29
Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive
More informationBreast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer
Breast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer Indication: Alternative palliative treatment for advanced breast cancer in patients where docetaxel monotherapy or docetaxel/capecitabine
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:
More informationBreast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer
Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer Indication: First-line or second-line treatment of triple negative advanced breast cancer National Cancer Drug Fund criteria: Advanced
More informationBreast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer
Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationFEC Docetaxel (NEOADJUVANT): Fluorouracil/ Epirubicin/ Cyclophosphamide followed by Docetaxel* in Early Breast Cancer
FEC Docetaxel (NEOADJUVANT): Fluouracil/ Epirubicin/ Cyclophosphamide followed by Docetaxel* in Early Breast Cancer Please, note that Neoadjuvant FEC-Docetaxel has only been approved f use in QEW Trust
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast
More informationHerceptin IV (Trastuzumab) and Paclitaxel Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Given as a three weekly schedule Day Drug Daily Dose Route Diluent & Rate On first cycle 250mls Normal Saline Herceptin IV 8 mg/kg Infusion only 90 mins On other 250mls Normal
More informationCarboplatin, Paclitaxel and Bevacizumab (gynae)
Carboplatin, Paclitaxel and Bevacizumab (gynae) Indication First line treatment of recurrent or metastatic cervical cancer. WHO performance status 0 or 1. First line treatment of advanced epithelial ovarian,
More informationBRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationCisplatin and Pemetrexed (NSCLC, mesothelioma)
Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as
More informationGemcitabine, Carboplatin and Bevacizumab (gynae)
Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10
More informationNCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel
More informationBreast Pathway Group EC x 4: Epirubicin & Cyclophosphamide in Early Breast Cancer
Breast Pathway Group EC x 4: & in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for moderate to high risk breast cancer Regimen details: 90 mg/m 2 IV Day 1 600 mg/m 2 IV Day 1 Administration:
More informationBreast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant therapy in early breast cancer Regimen details: Fluorouracil 600mg/m
More informationHerceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX)
Herceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX) DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent and Rate 1 to 21 Capecitabine 625mg/m 2 Day 1 TWICE DAILY Oral
More informationNCCP Chemotherapy Regimen. Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day cycle
Pertuzumab and Therapy - 21 day cycle INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients
More informationECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic
Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane
Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical
More informationPaclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen
Systemic Anti Cancer Treatment Protocol Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen PROTOCOL REF: MPHAPCECBR (Version No: 1.0) Approved for use in: Neoadjuvant treatment of operable,
More informationHCX Herceptin, Cisplatin and Capecitabine
DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent Rate Sodium Chloride 0.9% 250 ml Infusion Fast Running Day 1 Furosemide 20mg IV bolus Via saline drip Trastuzumab 8mg/kg
More informationCisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer
Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient
More informationBRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationNCCP Chemotherapy Protocol. Nab-Paclitaxel (Abraxane ) Monotherapy 21 day cycle
Nab-Paclitaxel (Abraxane ) Monotherapy 21 day cycle INDICATIONS FOR USE: INDICATION Treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and
More informationBRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
More informationNCCP Chemotherapy Regimen
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide
More informationE 90 C followed by Weekly Paclitaxel
E 90 C followed by Weekly Paclitaxel Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationLapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationNCCP Chemotherapy Regimen. DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Adjuvant treatment HER2 positive early breast cancer C50 00258a Hospital
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationRituximab (weekly) for Primary Cutaneous B cell Lymphoma
Rituximab (weekly) for Primary Cutaneous B cell Lymphoma Indication: Palliative therapy for Low grade Primary Cutaneous B cell Lymphoma (Primary cutaneous Follicle centre cell Lymphoma and Primary cutaneous
More informationTrastuzumab emtansine Kadcyla
Trastuzumab emtansine Kadcyla Indication Treatment of HER2 positive unresectable locally advanced or metastatic breast cancer for patients who have previously received a taxane and trastuzumab (Herceptin
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More informationCisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE:
Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE: Protocol INDICATION ICD10 Code Small cell lung cancer (SCLC) limited disease C34 00279a ELIGIBILTY: Indications as above ECOG 0-2
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationCarboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed
More informationBreast Pathway Group Oral Vinorelbine 3 weekly cycle in Advanced Breast Cancer
Breast Pathway Group Oral Vinorelbine 3 weekly cycle in Advanced Breast Cancer Indication: Regimen details: Administration: Frequency: Pre-medication: Anti- emetics: Supportive medication: Extravasation:
More informationCisplatin and Gemcitabine (bladder)
Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional
More informationLiposomal Doxorubicin (CAELYX) Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment
More informationABVD for Hodgkin s Lymphoma (LYMWOS008/1)
West of Scotland Cancer Network Chemotherapy Protocol Indication 1 st line treatment of Hodgkin s Lymphoma Eligibility Criteria ABVD for Hodgkin s Lymphoma (LYMWOS008/1) Confirmed diagnosis of Hodgkin
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationBEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL
Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician BRAJDCARBT Breast Dr. Susan Ellard
More informationEOX. Advanced / metastatic use: 8 cycles (CT scan after cycles 4 and 8)
EOX Page 1 of 6 As an alternative to ECX: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer For patients able to take oral medications Drugs/Dosage: Epirubicin 50mg/m 2 IV D1
More informationPACLitaxel Monotherapy 80mg/m 2 7 days
INDICATIONS FOR USE: PACLitaxel Monotherapy 80mg/m 2 7 days INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of metastatic breast carcinoma (mbc) in patients C50 00226a Hospital who have either
More informationBRAJACTTG. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group
More informationPaclitaxel Gastric Cancer
Systemic Anti Cancer Treatment Handbook Paclitaxel Gastric Cancer PROTOCOL REF: MPHAUGIPAC (Version No: 1.0) Approved for use in: Second line treatment of locally advanced and metastatic gastric / gastro-oesophageal
More informationNCCP Chemotherapy Regimen. Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day
INDICATIONS FOR USE: Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day Regimen INDICATION ICD10 Code Locally advanced or metastatic gastric carcinoma C16 00239a Locally advanced or metastatic oesophageal
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More informationCONSIDER ENTRY INTO CLINICAL TRIAL IF AVAILABLE/APPROPRIATE
West of Scotland Cancer Network Chemotherapy Protocol Capecitabine Adjuvant Colorectal Cancer (GIWOS-008) Capecitabine is an oral tumour-activated fluropyrimidine which as a result of the X-ACT trial has
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationNCCP Chemotherapy Regimen. FLOT Therapy-14 day
INDICATIONS FOR USE: FLOT Therapy-14 Regimen Code 00344a *Reimbursement Indicator INDICATION ICD10 Treatment of locally advanced ( T2) and/or nodal positive (N+) C16 resectable gastric adenocarcinoma Treatment
More informationCarboplatin and Paclitaxel (gynae)
Carboplatin and Paclitaxel (gynae) Indication Post surgical adjuvant or neoadjuvant or relapse therapy for stage IC to IV ovarian, fallopian tube or primary peritoneal cancer. First line or relapse therapy
More information5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy
5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Neoadjuvant treatment for breast carcinoma C50 00265a Adjuvant treatment for breast
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationNab-Paclitaxel (Abraxane) and Gemcitabine For Pancreatic Adenocarcinoma Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate 1 8 15 Sodium Chloride 0.9% 100ml Infusion Fast Running Dexamethasone 8mg Oral Ondansetron 8mg Oral/ IV Chlorphenamine 10mg Intravenous Slow
More informationCEPP for Diffuse Large B Cell Lymphoma (LYMWOS005/1)
West of Scotland Cancer Network Chemotherapy Protocol CEPP for Diffuse Large B Cell Lymphoma (LYMWOS005/1) Indication First line treatment of Diffuse Large B Cell Lymphoma (DLBCL) in patients who are unfit
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationNCCP Chemotherapy Regimen. Obinutuzumab Maintenance Therapy following O-Bendamustine therapy
Obinutuzumab following O-Bendamustine therapy INDICATIONS FOR USE: INDICATION Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationNCCP Chemotherapy Regimen
Carboplatin (AUC 2) Weekly and Paclitaxel (50mg/m 2 ) Weekly with Radiotherapy (RT) -5 weeks INDICATIONS FOR USE: Regimen Code 00422a *Reimbursement Indicator INDICATION ICD10 Preoperative chemoradiation
More informationCarboplatin / Gemcitabine Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously
More informationExcipients: Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT TAXOTERE 20 mg/1 ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains
More information1. NAME OF THE MEDICINAL PRODUCT
1. NAME OF THE MEDICINAL PRODUCT TAXOTERE 20mg/1ml concentrate for solution for infusion TAXOTERE 80mg/4ml concentrate for solution for infusion TAXOTERE 160mg/8ml concentrate for solution for infusion
More information